

Friday, 5 November 2021

The Manager  
Market Announcement Office  
Australian Securities Exchange Limited  
20 Bridge Street  
Sydney NSW 2000

**REGENEUS LTD (ASX:RGS)**

**NEW LIFE SCIENCES PLACEMENT AGREEMENT - EXTENSION OF SECOND CLOSING DATE**

**Regeneus Ltd (ASX: RGS) (Regeneus or the Company)**, a clinical-stage regenerative medicine company, today announced that it has agreed to extend by 60 days the date by which the second placement of the Company's shares to New Life Sciences Capital, LLC (**New Life Sciences**) is to occur.

Regeneus announced on 7 May 2021 that it secured up to \$4.5 million in a three-stage placement of the Company's ordinary shares (**Shares**) to New Life Sciences, a U.S.-based institutional investor, comprising:

- an initial placement of \$1,590,000 of Shares to raise \$1,500,000 which occurred on 12 May 2021;
- a second placement of \$1,590,000 of Shares to raise \$1,500,000 which was to occur by 8 November 2021 and, as a result of the extension, will now occur by 7 January 2022; and
- a third placement of \$1,500,000 of Shares to raise \$1,500,000 will occur, subject to the mutual consent of the Investor and the Company, within 12 months.

Further details regarding the terms of the placement to New Life Sciences are set out in the Company's ASX announcement dated 7 May 2021.

The extension of the date by which the second placement is to occur accords with Regeneus's current funding requirements.

**-ENDS-**

**About Regeneus**

Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza™ and Sygenus. Visit [www.regeneus.com.au](http://www.regeneus.com.au) for more information.

**Authorisation & Additional information**

This announcement was authorised by the Chairman and Company Secretary of Regeneus Ltd

**Investor and Media Contact**

WE Communications  
T: 03 8866 1200  
E: [WE-AURegeneus@we-worldwide.com](mailto:WE-AURegeneus@we-worldwide.com)